KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Inventory (2020 - 2026)

Esperion Therapeutics filings provide 6 years of Inventory readings, the most recent being $105.1 million for Q4 2025.

  • On a quarterly basis, Inventory rose 11.25% to $105.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $105.1 million, a 11.25% increase, with the full-year FY2025 number at $105.1 million, up 11.25% from a year prior.
  • Inventory hit $105.1 million in Q4 2025 for Esperion Therapeutics, down from $108.5 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $114.5 million in Q2 2025 to a low of $20.0 million in Q1 2021.
  • Median Inventory over the past 5 years was $48.6 million (2023), compared with a mean of $60.2 million.
  • Biggest five-year swings in Inventory: surged 988.0% in 2021 and later decreased 13.03% in 2022.
  • Esperion Therapeutics' Inventory stood at $34.4 million in 2021, then increased by 2.35% to $35.2 million in 2022, then skyrocketed by 86.42% to $65.6 million in 2023, then skyrocketed by 43.99% to $94.5 million in 2024, then grew by 11.25% to $105.1 million in 2025.
  • The last three reported values for Inventory were $105.1 million (Q4 2025), $108.5 million (Q3 2025), and $114.5 million (Q2 2025) per Business Quant data.